14/11/2016 11:19:07

NeuroSearch found guilty of market manipulation in Supreme Court case

Related content
04 Jul - 
NeuroSearch and Saniona enter into agreement on transfe..
21 Mar - 
Report on Annual General Meeting of NeuroSearch A/S
07 Mar - 
Report pursuant to section 28a of the Danish Act on Sec..
Related debate
05 Jul - 
Er det kursen på Neurosearch eller Saniona, som v..
04 Jul - 
Lyder kryptisk! Hvad bygger du det på?
04 Jul - 
Kursen vil stige.   Taastrup

Announcement

14 November 2016

The Danish Supreme Court today upheld the Eastern High Court’s decision in a case in which the State Prosecutor for Serious Economic and International Crime had charged NeuroSearch with market manipulation contrary to the Danish Securities Trading Act and the Market Abuse Regulation. The company was further ordered to pay a fine of DKK 5 million.

The charge was brought following NeuroSearch’s announcement in February 2010 in which the company reported top-line results from a clinical phase III study on its drug candidate Huntexil®.

Chairman of the board of directors, Karin Garre, says in a comment:

"It is very regrettable that the Supreme Court has decided to uphold the High Court’s judgment considering that the High Court acquitted the company’s former CEO on the same count. NeuroSearch of course will respect the Supreme Court's ruling that the company is responsible for the announcement concerning the outcome of a clinical study in 2010 contained misleading signals about the market price so that it amounted to market manipulation. This does not reflect NeuroSearch’s view of the situation and that is why we decided to refer the matter to the Supreme Court. With this ruling, the company will work with a view to rapidly decide the future of the company.”

Following the Supreme Court judgment, the board of directors will now assess NeuroSearch’s future and provide the shareholders with the board’s recommendations on the steps to be taken.

The judgment does not affect the company’s expectations for the annual results in 2016.

Karin Garre                                                 Allan Andersen

Chairman of the Board                                CEO

Contact

Allan Andersen, CEO, telephone: +454016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on NASDAQ Copenhagen A/S.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Form 8.5 (EPT/RI) - Tesco plc

21/08/2017 07:43:02
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

18/08/2017 15:36:47
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Prima BioMed Appoints Non-Executive Director to the Board
2
Gamers Get First Chance to Play Xbox One X at GameStop Expo
3
Saniona AB: Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity
4
Cecilie B. Heuch appointed EVP and Chief People Officer of Telenor Group
5
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria

Related stock quotes

NeuroSearch A/S 3.62 0.6% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 August 2017 13:13:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB2 - 2017-08-21 14:13:26 - 2017-08-21 13:13:26 - 1000 - Website: OKAY